Sector Expert: John McCamant

Medical Technology Stock Letter

Image: John McCamant

John McCamant is the editor of the Medical Technology Stock Letter, a leading investment newsletter. McCamant has spent 25 years on the frontlines of biotechnology investing. He has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Reuters, Bloomberg, CBS and Marketwatch.

The Medical Technology Stock Letter has earned the #1 ranking from Hulbert's Financial Digest. >Read More

Subscribe to
Streetwise Reports

Companies Commented On

  • Anthera Pharmaceuticals Inc.
  • Cellular Biomedicine Group Inc.
  • Novavax Inc.
  • OncoGenex Pharmaceuticals Inc.
  • Sangamo BioSciences Inc.
  • The Medicines Company


Recent Interviews

Fallen Biotech Angels to Arise: John McCamant and Jay Silverman of the Medical Technology Stock Letter (9/16/15)
multicoloredbeakers580

It's all about data for John McCamant and Jay Silverman of the Medical Technology Stock Letter, and right now it's festival time as we approach the busy season of market-moving catalysts and milestones. From now until December, biotech investors will be focused on the press releases, webinars and scientific presentations that serve as a vitality tonic for the entire biotech industry. In this interview with The Life Sciences Report, McCamant and Silverman give a detailed picture of their growth theories on six biotech stocks that could reap many multiples on invested capital over the next few years.

Fire Up the Immune System to Fight Cancers and Boost Portfolios: John McCamant (5/12/15)
Cancer research

An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.

Will Biotech Fire on All Cylinders in 2015? (12/30/14)
2015aheadroad580

Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early 2014 before rebounding, essentially following the upward trend that most experts forecast. What is in store for 2015? The Life Sciences Report turned to newsletter writer John McCamant and WBB Securities' Steve Brozak for insight.

Recent Quotes

"CBMG is putting together a huge portfolio of assets in cancer."

The Life Sciences Report Interview with John McCamant (9/16/15)
more >

"CBMG's world-class pipeline is still below Wall Street's radar."

— John McCamant, Medical Technology Stock Letter (6/11/15)
more >

"CBMG is a recently transformed company."

The Life Sciences Report with John McCamant (5/12/15)
more >

"We continue to believe that OGXI is undervalued."

— John McCamant, Medical Technology Stock Letter (12/21/12)
more >

"The potential of CYCC's phase 3 trial with AML gives the Street more confidence."

The Life Sciences Report Interview with John McCamant (10/25/12)
more >

"If OGXI-011 starts delivering in phase 3, OGXI could be a five- or tenbagger."

The Life Sciences Report Interview with John McCamant (10/4/12)
more >

"We continue to believe that OGXI is undervalued."

— John McCamant, Medical Technology Stock Letter (7/20/12)
more >

"Data from OGXI's phase 2 trial for OGX-427 is encouraging."

— John McCamant, Medical Technology Stock Letter (6/8/12)
more >



Due to permission requirements, not all quotes are shown.